Lyell Immunopharma (LYEL) 10-Q2024 Q3 Quarterly report

Filed: 7 Nov 24, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: alter, ASH, autoimmune, axicabtagene, bilateral, Bio, bispecific, BLA, bone, capped, cent, central, China, chosen, ciloleucel, Claudin, Conference, conventional, correctly, Corrupt, costimulatory, density, diffuse, digit, editing, endpoint, energy, engraftment, Fast, faster, follicular, fractional, gate, gradual, histologic, ImmPACT, Immunology, inhibit, Inspire, intermediate, internationally, JR, learned, living, logarithmic, logic, Los, lymphoma, mantle, marketplace, marrow, median, mediastinal, Medicine, merged, Multiomic, nearest, NEJM, NHL, operationally, outbreak, penetrate, presence, ratio, rationally, recommended, Regenerative, renegotiate, repetitive, reprioritized, resource, restimulation, RMAT, robust, rolling, rounded, serial, shipping, singularly, spending, surrogate, tandem, tension, therewith, thousand, tolerability, tolerance, transportation, UCLA, undergone, USA, Westin, winding, window, WT

Removed: aim, applying, cervical, cetuximab, colorectal, CRC, creating, demonstrating, effectuated, EGFR, EGFRopt, EMA, epigenetically, eradicate, expanded, expression, genetically, goal, head, highest, immunohistochemistry, immunosuppressive, improving, intracellular, locally, measure, media, melanoma, metastatic, microenvironment, monoclonal, mortality, mutational, neck, pancreatic, peripheral, polyclonality, post, producing, rabbit, refractory, regimen, relapsed, request, screening, shorten, spacer, tracking, transmembrane, treating, truncated, version

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

LYEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), each of the undersigned hereby certifies in her or his capacity as an officer of Lyell Immunopharma, Inc, Inc. (the “Company”), that, to the best of her or his knowledge:

(1)The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 7, 2024	By:	/s/ LYNN SEELY
		Lynn Seely, M.D.
		President and Chief Executive Officer (Principal Executive Officer)


Date: November 7, 2024	By:	/s/ CHARLES NEWTON
		Charles Newton
		Chief Financial Officer (Principal Financial and Accounting Officer)